This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Callahan, M. J. Articles by Muto, M. G. Search for Related Content PubMed PubMed Citation Articles by Callahan, M. J. Articles by Muto, M. G. Social Bookmarking                            What's this?

Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction

Michael J. Callahan, Christopher P. Crum, Fabiola Medeiros, David W. Kindelberger, Julia A. Elvin, Judy E. Garber, Colleen M. Feltmate, Ross S. Berkowitz, Michael G. Muto

From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Division of Women's and Perinatal Pathology, Department of Pathology Brigham and Women's Hospital; and Cancer Risk and Prevention Program, Dana-Farber Cancer Institute, Boston, MA

Address reprint requests to Michael G. Muto, MD, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115; e-mail: mmuto{at}partners.org

Purpose To review the frequency and location of malignancies detected after prophylactic salpingo-oophorectomy in women with BRCA mutations.

Methods Medical records and pathology findings were reviewed from BRCA-positive women undergoing prophylactic surgery for ovarian cancer risk reduction who underwent complete examination of the adnexa. Patients undergoing this procedure between January 1999 and January 2007 were identified.

Results From January 1999 to January 2007, 122 BRCA-positive patients underwent prophylactic surgery in the Division of Gynecologic Oncology at Brigham and Women's Hospital. The median age was 46.5 years (range, 33 to 76 years). Seven (5.7%) were found to have an early malignancy in the upper genital tract and all patients were age 44 years at diagnosis. Of seven consecutive cancers culled between January 1999 and January 2007, all (100%) originated in the fimbrial or ampullary region of the tube; six had an early (intraepithelial) component. Two were associated with surface implants on the ovary and two required repeated sectioning to detect microscopic carcinomas in the fimbria.

Conclusion The distal fallopian tube seems to be the dominant site of origin for early malignancies detected in approximately 6% of women undergoing ovarian cancer risk-reduction surgery. The greatest proportion of serous cancer risk in BRCA mutation–positive women should be assigned to the fimbria rather than the ovary, and future clinical and research protocols should employ thorough examination of the fimbria, including multiple sections from each tissue block, to maximize detection of early malignancies in this population.

Presented in part at the New England Association of Gynecologic Oncologists 25th Annual Meeting, June 2-5, 2005, Bretton Woods, NH, and the Society of Gynecologic Oncologists 37th Annual Meeting, March 22-26, 2006, Palm Springs, CA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Hickey, M. Peate, C.M. Saunders, and M. Friedlander Breast cancer in young women and its impact on reproductive function Hum. Reprod. Update, May 1, 2009; 15(3): 323 - 339. [Abstract] [Full Text] [PDF]

				J. S Fleming, H J. McQuillan, M. J Millier, and G. C Sellar Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract Reproduction, April 1, 2009; 137(4): 721 - 726. [Abstract] [Full Text] [PDF]

				K. Levanon, C. Crum, and R. Drapkin New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact J. Clin. Oncol., November 10, 2008; 26(32): 5284 - 5293. [Abstract] [Full Text] [PDF]

				J. W. Carlson, A. Miron, E. A. Jarboe, M. M. Parast, M. S. Hirsch, Y. Lee, M. G. Muto, D. Kindelberger, and C. P. Crum Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention J. Clin. Oncol., September 1, 2008; 26(25): 4160 - 4165. [Abstract] [Full Text] [PDF]